Much of the talk about the U.S. patent system generates a lot of heat, but little light. We hear complaints about how the system doesn't work and varied suggestions for fixing it. However, it's not really broken.
The presidential hopeful is harder on Big Pharma than he is on Wall Street.
Those approaches were not taken by the 2011 patent reform bill. Rather than decrease the overall patent load, the legislation
Far from encouraging innovation and advancement in the "useful arts," software and business method patents have become a quasi-legal poison pill.